Overview

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

Status:
Withdrawn

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether patients treated with Radiofrequency Ablation (RFA) in conjunction with chemotherapy have a better overall survival rate than patients treated with chemotherapy alone.

Phase:

Phase 4

Details

Lead Sponsor:

Boston Scientific Corporation

Treatments:

Cetuximab
Irinotecan
Oxaliplatin